Reactivity to β2 glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis

Thrombosis and Haemostasis

Volumn 75, Issue 5, 1996, Pages 717-720

  Forastiero, R R ^a   Martinuzzo, M E ^a   Kordich, L C ^b   Carreras, L O ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G;

ANTIBODY AFFINITY; ANTIBODY DETECTION; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; SYPHILIS;

EID: 0029897454     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650354     Document Type: Article

References (35)

1. Harris EN. Annotation. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9.
2. Exner T, Triplett DA. Lupus anticoagulants: characteristics, methods of laboratory detection and some clinical associations. In: Phospholipid-Binding Antibodies. Harris EN, Exner T, Hughes GRV, Asherson RA, eds. Boca Raton, Florida (USA). CRC Press 1991; 141-58.
3. Harris EN. The Second International Anticardiolipin Standardization Workshop/The Kingston Antiphospholipid Antibody (KAPS) Study Group. Am J Clin Pathol 1990; 94: 476-84.
4. Harris EN. The antiphospholipid syndrome - an introduction. In: Phospholipid-Binding Antibodies. Harris EN, Exner T, Hughes GRV, Asherson RA, eds. Boca Raton, Florida (USA). CRC Press 1991; 373-86.
5. Meyer O, Cyna L, Bourgeois P, Kahn MF, Ryckewaert A. Profile and cross-reactivities of antiphospholipid antibodies in systemic lupus erythematosus and syphilis. Clin Rheumatol 1987; 6: 369-77.
6. Koike T, Sueishi M, Funaki H, Tomioka H, Yoshida S. Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus. Clin Exp Immunol 1984; 56: 193-9.
7. Harris EN, Gharavi AE, Wasley GD, Hughes GRV. Use of an enzymelinked immunosorbent assay and of inhibition studies to distinguish between antibodies to cardiolipin from patients with syphilis or autoimmune disorders. J Infect Dis 1987; 157: 23-31.
8. Levy RA, Gharavi AE, Sammaritano LR, Habina L, Qamar T, Lockshin MD. Characteristics of IgG antiphospholipid antibodies in patients with systemic lupus erythematosus and syphilis. J Rheumatol 1990; 17: 1036-41.
9. Ordi J, Selva A, Monegal F, Porcel JM, Martinez-Costa X, Vilardell M. Anticardiolipin antibodies and dependence of a serum cofactor. A mechanism of thrombosis. J Rheumatol 1993; 20: 1321-4.
10. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, KoikeT. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990; 336: 177-8.
11. Galli M, Comfurius P, Maassen C, Hemker HC, De Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-7.
12. 2 glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
13. 2 glycoprotein I as an antigen. J Immunol Methods 1991; 143: 223-9.
14. 2 glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992; 93: 181-6.
15. 2 glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 1994; 179: 457-62.
16. 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995; 73: 29-34.
17. 2 glycoprotein I: detection and association with thrombosis. Br J Haematol 1995; 89: 397-402.
18. 2 glycoprotein I in the absence of phospholipid. Importance of antigen density and bivalent binding. J Immunol 1995; 154: 954-60.
19. Pengo V, Biasiolo A. Purification of anticardiolipin and lupus anticoagulant activities by using cardiolipin immobilized on agarose beads. Thromb Res 1993; 72: 423-30.
20. Bradford MM. A rapid and sensitive method for the quantification of microgram quantitatives of protein utilizing the principle of protein dyebinding. Anal Biochemistry 1976; 72: 248-54.
21. Chamley LW, McKay EJ, Pattison NS. Cofactor dependent and cofactor independent anticardiolipin antibodies. Thromb Res 1991; 61: 291-9.
22. Sammaritano LR, Lockshin MD, Gharavi AE. Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus 1992; 1: 83-90.
23. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Suzuki T, Sumida T, Yasuda T, Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J immunol 1992; 148: 3885-91.
24. Harris EN, Pierangeli S, Barquinero J, Ordi-Ros J. Anticardiolipin antibodies and binding of anionic phospholipids and serum protein. Lancet 1991; 336: 505-6.
25. 2GPI) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies. Br J Haematol 1992; 82: 565-70.
26. 2GPI and role of other phospholipid cofactors. Haemostasis 1994; 24: 191-203.
27. 2-Glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1992; 1: 75-81.
28. 2-glycoprotein I dependent (systemic lupus erythematosus type) and independent (syphilis type) anticardiolipin antibody with Tween 20. Br J Haematol 1993; 85: 799-802.
29. 2-Glycoprotein I-dependent and -independent anticardiolipin antibodies in healthy pregnant women. Human Reprod 1994; 9: 1849-51.
30. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987; 68: 215-22.
31. 2GP-I). Lupus 1994; 3: 329.
32. 2-glycoprotein-I in the absence of phospholipid. Br J Haematol 1992; 82: 571-4.
33. 2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 1994; 95: 310-5.
34. 2-glycoprotein-I contains a phospholipid binding site (cys 281-cys 288) and a region recognized by anticardiolipin antibodies. J Immunol 1994; 152: 653-9.
35. 2-glycoprotein-I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 361-5.